Findings from this phase 4 study call for a re-evaluation of the current WHO and CDC guidelines of isoniazid preventive therapy for the prevention of tuberculosis in pregnant women with HIV.
Interim results from this open-label extension trial of the dapivirine ring demonstrate high uptake and adherence, and HIV-1 incidence has been half of the expected rate.
A phase 3 study evaluating HIV patients who switched to treatment with Biktarvy found this combination therapy to be statistically noninferior to a regimen containing abacavir,
